Clinical trial
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of…
NCT00396266 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00396266 |
|---|---|
| Title | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF |
| Official title | Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma, Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | G-CSF Plus Plerixafor |
| Enrollment | 22 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 6, 2006 |
| Last update posted | Mar 7, 2014 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: